Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Cancer Res. 2011 Jul 27;71(18):6030–6039. doi: 10.1158/0008-5472.CAN-10-2719

Figure 5. In vivo Dll4 silencing: DLL4 gene silencing in vivo in the A2780 (a) and SKOV3ip1 (b) models of ovarian cancer.

Figure 5

Mice were randomly allocated to eight groups (n=10 mice per group) and underwent treatment as follows: (1) control siRNA; (2) mouse Dll4 siRNA; (3) human Dll4 siRNA; (4) mouse Dll4 siRNA plus human Dll4 siRNA; (5) bevacizumab; (6) bevacizumab plus mouse Dll4 siRNA; (7) bevacizumab plus human Dll4 siRNA; (8) bevacizumab plus human Dll4 siRNA and mouse Dll4 siRNA. Mice were euthanized when animals appeared moribund because of significant tumor burden (4 to 5 weeks after cell injection depending on the cell line). *p< 0.05, in compared with control group; †‡ p<0.01, in compared with bevacizumab treatment group.